Tag: PCR LV 2018

Olaf Wendler

Olaf Wendler (lead for Cardiothoracic Surgery, King’s Health Partners, and chair of the Heart and Vascular Institute of the Cleveland Clinic London, UK) performed...

PCR LV 2018: One-year results of VIVA confirm safety and efficacy...

Speaking at PCR London Valves (9–11 September, London, UK) Didier Tchétché (Clinique Pasteur, Toulouse, France) reported that the one-year results of the VIVA (valve-in-valve)...

PCR LV 2018: Early discharge feasible for unselected TAVI patients

Data from the multicentre FAST-TAVI trial indicate that early discharge—discharge within 72 hours—in an all-comers population undergoing transcatheter aortic valve implantation (TAVI) is safe...

PCR LV 2018: Favourable outcomes for next-generation Acurate neo2 TAVI system

A new study evaluating the safety and performance of the Acurate neo2 (Boston Scientific) transcatheter aortic valve implantation (TAVI) system demonstrated a high procedural...